- Approval Id
- 8ef37f4f46fffb41
- Drug Name
- OMNIPAQUE INJECTION 300 MG I/ML
- Product Name
- OMNIPAQUE INJECTION 300 MG I/ML
- Approval Number
- SIN05924P
- Approval Date
- 1991-05-17
- Registrant
- GE HEALTHCARE PTE. LTD.
- Licence Holder
- GE HEALTHCARE PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- INJECTION
- Dosage
- <p><strong>4.2 POSOLOGY AND METHOD OF ADMINISTRATION</strong></p>
<p>The dosage varies depending on the type of examination, age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume is used as with other iodinated X-ray contrast media in current use. Adequate hydration should be assured before and after administration as for other contrast media.<br>
For intravenous, intra-arterial and intrathecal use, and use in body cavities.<br>
The following dosages may serve as a guide.</p>
<p><strong>Guidelines for intravenous use</strong></p>
<img src="/TGIF/Omnipaque-Table1_180424.png" alt="Omnipaque Dosage Table 1" /><br><br>
<p><strong>Guidelines for intra-arterial use</strong></p>
<img src="/TGIF/Omnipaque-Table2_180424.png" alt="Omnipaque Dosage Table 2" /><br><br>
<p><strong>Guidelines for intrathecal use</strong></p>
<img src="/TGIF/Omnipaque-Table3_180424.png" alt="Omnipaque Dosage Table 3" /><br><br>
<p>To minimize possible adverse reactions a total dose of 3 g iodine should not be exceeded.</p>
<p><strong>Guidelines for Body cavities</strong></p>
<img src="/TGIF/Omnipaque-Table4_180424.png" alt="Omnipaque Dosage Table 4" /><br><br>
- Route Of Administration
- INTRAVENOUS, INTRAVASCULAR, INTRACAVITARY, INTRA-ARTERIAL, INTRATHECAL
- Indication Info
- <p><strong>4.1 THERAPEUTIC INDICATIONS</strong></p>
<p>This medicinal product is for diagnostic use only.<br>
X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT-enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract.</p>
- Contraindications
- <p><strong>4.3 CONTRAINDICATIONS</strong></p>
<p>Hypersensitivity to the active substance or to any of the excipients (See Section <strong>6.1 LIST OF EXCIPIENTS</strong> – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>)<br>
Manifest thyrotoxicosis.</p>
- Atc Code
- V08AB02
- Atc Item Name
- iohexol
- Pharma Manufacturer Name
- GE HEALTHCARE PTE. LTD.
